Dr. Reddy's launches nivolumab biosimilar in India

Dr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to enhance immune response against a variety of cancers, this new treatment has received approval from the DCGI for twelve specific indications. By making this intravenous therapy available, Dr Reddy's aims to broaden access to affordable, high-quality cancer care options for patients in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T2NwOSC
via IFTTT